Cardiovascular pharmacology of the A(2A) adenosine receptor antagonist, SCH 58261, in the rat

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 1, 1998, Pages 9-15

  Monopoli, Angela ^a   Casati, Carlo ^a   Lozza, Gianluca ^a   Forlani, Angelo ^a   Ongini, Ennio ^a  

^a Schering Plough Research Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADRENERGIC RECEPTOR BLOCKING AGENT; PHENTOLAMINE; PROPRANOLOL DERIVATIVE; ADENOSINE RECEPTOR; PROPRANOLOL; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIASTOLIC BLOOD PRESSURE; HEART RATE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; HEMODYNAMICS; MALE; SPRAGUE DAWLEY RAT;

ADRENERGIC ANTAGONISTS; ANIMALS; BLOOD PRESSURE; DRUG INTERACTIONS; HEART RATE; HEMODYNAMIC PROCESSES; MALE; PHENTOLAMINE; PROPRANOLOL; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; TRIAZOLES;

EID: 0031594199     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 2a adenosine receptor antagonists. Bioorg Med Chem Lett 4:2539-2544.
2. Barraco RA, El Ridi MR, Ergene E and Phillis JW (1991) Adenosine receptor subtypes in the brainstem mediate distinct cardiovascular response patterns Brain Res Bull 26:59-84.
3. Barraca RA, Clough Helfman C, Goodwin BP and Anderson GF (1995) Evidence for presynaptic adenosine A2a receptors associated with norepinephrine release and their desensitization in the rat nucleus tractus solitarius. J Neurochem 65:1604-1611.
4. Barraco RA, Clough Helfman C and Anderson GF (1996) Augmented release of serotonin by adenosine A(2a) receptor activation and desensitization by CGS 21680 in the rat nucleus tractus solitarius. Brain Res 733:155-161.
5. 3H]SCH58261 to coronary artery membranes. Circ Res 79:1153-1160.
6. 2A adenosine receptor blockade by SCH 58261 mediates coronary vasodilation in guinea pig hearts. J Pharmacol Exp Ther, in press.
7. Benorelli R, Ferri N, Adami M and Ongini E (1996) Effects of selective agonists and antagonists for A1 or A(2A) adenosine receptors on sleep-waking patterns in rats. Drug Dev Res 37:65-72.
8. 3H]nitrobenzyl-thioinosine. J Neurosci 5:544-550.
9. Bonizzoni E, Milani S, Ongini E, Casati C and Monopoli A (1995) Modeling hemoduiamic profiles by telemetry in the rat: A study with A1 and A(2a) adenosine agonists. Hypertension 25:564-569.
10. Casati C, Monopoli A, Forlani A, Bonizzoni E and Ongini E (1995) Telemetry monitoring of hemodynamic effects induced over time by adenosine agonists in spontaneously hypertensive rats. J Pharmacol Exp Ther 275:914-919.
11. Dinisotti S, Conti A, Sandoli D, Zocchi C, Gatta F and Ongini E (1994) Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br J Pharmacol 112:659-665.
12. 3H]SCH 58261. J Pharmacol Exp Ther 278:1209-1214.
13. 3H]-SCH 58261. Br J Pharmacol 121:353-360.
14. Fredholm B (1984) The Methylxanthine Beverages and Food: Chemistry, Consumption, and Health Effects, pp 303-330, Alan R. Liss, New York, NY.
15. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P and Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
16. 2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 70:1210-1216.
17. Jackson EK, Herzer WA and Suzuki F (1993) KF17837 is an A2 adenosine receptor antagonist in vivo. J Pharmacol Exp Ther 267:1304-1310.
18. 2-selective adenosine antagonists. J Med Chem 36:1333-1342.
19. Keddie JR, Poucher SM, Shaw GR, Brooks R and Collis MG (1996) In vivo characterization of ZM 241385, a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 301:107-113.
20. 3 receptor subtype. J Med Chem 39:4142-4148.
21. 2A receptor. Nature 388:674-678.
22. Mayfield RD, Suzuki F and Zahniser NR (1993) Adenosine A2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J Neurochem 60:2334-2337.
23. Monopoli A, Conti A, Dionisotti S, Casati C, Camaioni E, Cristalli G and Ongini E (1994a) Pharmacology of the highly selective A1 adenosine receptor agonist 2-chloro-N6-cyclopentyladenosine. Arzneim Forsch. Drug Res 44:1305-1312.
24. Monopoli A, Conti A, Zocchi C, Casati C, Volpini R, Cristalli G and Ongini E (1994b) Pharmacology of the new selective A(2a) adenosine receptor agonist 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneim Forsch Drug Res 44:1296-1304.
25. Monopoli A, Casati C, Forlani A, Marzanatti M and Ongini E (1996) The in vivo cardiovascular pharmacology of the selective A2a adenosine antagonist SCH 58261 in the rat and rabbit. Br J Pharmacol 117:279P.
26. Nonaka H, Ichimura M, Takeda M, Nonaka Y, Shimada J, Suzuki F, Yamaguchi K and Kase H (1994) KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur J Pharmacol 267:335-341.
27. Olah ME and Stiles GL (1995) Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581-606.
28. Olsson RA and Pearson JD (1990) Cardiovascular purinoceptors. Physiol Rev 70: 761-845.
29. 2A receptors. Trends. Pharmacol Sci 17:364-372.
30. Poucher SM, Keddie JR, Singh P, Stoggall SM, Caulkett PW, Jones G and Coll MG (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br J Pharmacol 115:1096-1102.
31. Poucher SM, Keddie JR, Brooks R, Shaw GR and Mckillop D (1996) Pharmacodynamics of ZM 241385, a potent A(2a) adenosine receptor antagonist, after enteric administration in rat, cat and dog. J Pharm Pharmacol 48:601-606.
32. Robertson D, Wade D, Workman R, Woosley RL and Oates JA (1981) Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 67:1111-1117.
33. Sala C, Monopoli A, Alberti C, Casati C, Ongini E, Zanchetti A and Morganti A (1996) Humoral effects of selective adenosine agonists in spontaneously hypertensive rats. J Hypertens 14:75-79.
34. SAS/Stat Guide for Personal Computers, Version 6 (1989) pp 1135-1193, Sas Institute Inc., Cary, NC.
35. Schlack W, Schafer M, Uebing A, Schafer S, Borchard U and Thamer V (1993) Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 22:89-96.
36. Tao S and Abdel Rahman AA (1993) Neuronal and cardiovascular responses to adenosine microinjection into the nucleus tractus solitarius. Brain Res Bull 32: 407-417.
37. Webb RL, Mcneal RB, JR, Barclay BW and Yasay GD (1990) Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat. J Pharmacol Exp Ther 254:1090-1099.
38. Williams M, Francis J, Ghai G, Braunwalder A, Psychoyos S, Stone GA and Cash WD (1987) Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist. J Pharmacol Exp Ther 241:415-420.
39. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG and Dionisotti S (1996a) The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. J Pharmacol Exp Ther 276:398-404.
40. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 117:1381-1386.